Weight-Loss Jabs Show No Clear Rise in Suicidal Thoughts
Graded Moderate — a structured search found 20 studies, including large analyses of randomized trials; much of the data is observational and people with serious mental illness were often left out.
- Design
- Systematic review
- Participants
- 20
- Duration
- —
- Funding
- —
In the studies reviewed, weight-loss injections showed no meaningful rise in suicidal thoughts or depression.
Weight-loss and diabetes injections such as semaglutide and the related drug tirzepatide raised concerns about depression and suicidal thoughts. Drug regulators in Europe and the US looked into it. A new review of the evidence is reassuring: the studies do not point to a meaningful rise in mental health harm.
The authors searched four large medical databases and found 20 suitable studies plus two regulatory reviews. In trials where chance decided who got the drug or a dummy injection, suicidal thoughts, depression and anxiety were not more common. In tirzepatide trials, 0.6 percent reported suicidal thoughts on the drug and on the dummy alike. Patient records from the US, Scandinavia and the UK also showed no clear increase compared with other diabetes drugs.
Warning signals came mainly from systems where doctors and patients report side effects. Those reports cannot tell a drug effect apart from mental strain people already had. One limit stands out: people with serious mental illness were often excluded from the trials. For them, and for rare long-term effects, the authors say monitoring should continue.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Topics
